Version June 2024
| CALGB studies | |||
| Study | Dates | Response, % | MST, months |
| #8435 (Mitomycin/cisplatin) | 6/84-10/86 | 26 | 8.1 |
| 14 | 8.8 | ||
| #8638 (Carboplatin) | 2/87-2/88 | 7 | 7.1 |
| #8833 (DHAC) | 6/88-6/89 | 17 | 6.7 |
| #8933 (Trimetrexate) | 7/89-8/91 | 12 | 3.9 |
| 12 | 9.8 | ||
| #9031 (DHAC/cisplatin) | 7/90-7/93 | 14 | 6.4 |
| #9131 (Edatrexate) | 5/92-9/94 | 25 | 9.6 |
| 18 | 6.9 | ||
| #9234 (Paclitaxel) | 3/93-9/94 | 9 | 5 |
| Poor prognostic factors in multivariate analysis | |||
| Variable | Relative risk | ||
| Pleural disease | Present | 2.64 | |
| Lactic dehydrogenase (LDH) | >500 IU/L | 1.91 | |
| Poor performance status (PS) | PS1 | 1.65 | |
| PS2 | 2.71 | ||
| Platelet count | >400,000/microL | 1.57 | |
| Epithelial histology | Absent | 1.33 | |
| Age | Each year over 75 yo | 1.34 | |
| CALGB prognostic groups | |||
| Group | Characteristics | MST, months | |
| Group I | PS, 0; age <49 years | 12.5 | |
| PS, 0; age ≥49 years; HGB* ≥14.6 | 14.5 | ||
| Group II | PS, 1 or 2; WBC* < 8.7; no chest pain | 9.5 | |
| Group III | PS, 0; age >49 years; HGB <14.6 | 9.3 | |
| PS, 1 or 2; WBC < 15.6; chest pain; weight loss; HGB ≥ 12.3 | 9.3 | ||
| PS, 1 or 2; 9.8 ≤ WBC < 15.6; chest pain; weight loss; HGB ≥ 11.2 | 9.6 | ||
| Group IV | PS, 1 or 2; 8.7 ≤ WBC <15.6; no chest pain | 6.6 | |
| Group V | PS, 1 or 2; WBC <15.6; chest pain; no weight loss; HGB <12.3 | 3.9 | |
| PS, 1 or 2; 9.8 ≤ WBC <15.6; chest pain; weight loss; HGB <11.2 | 4.9 | ||
| PS, 1 or 2; WBC < 9.8; chest pain; weight loss | 3.9 | ||
| Group VI | PS, 1 or 2; WBC ≥ 15.6 | 1.4 | |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
